This editorial refers to 'Regulation of oxidized platelet lipidome: implications for coronary artery disease' ‡ , by M. Chatterjee et al., on page 1993.
Novel biomarkers that accurately report the risk of cardiovascular events such as myocardial infarction have long been sought after. This is driven by the need to inform clinical diagnostic pathways and to optimize therapeutic approaches with the ultimate aim of reducing cardiovascular mortality and morbidity. Technical advances in the sensitivity, precision, and throughput of analytical instruments have recently facilitated unprecedented profiling approaches to identify specific mRNA, microRNA, genetic, proteomic, metabolomic, and, most recently, lipidomic profiles associated with cardiovascular risk. 1,2 Plasma has been the major compartment utilised in such profiling studies, while urine has also attracted interest, particularly for proteomic profiling. 2, 3 In this issue of the journal, Chatterjee et al. 4 go a step further and perform lipidomic profiling in patients with coronary artery disease in a specific cellular compartment of the blood-the platelet. Platelets are central players in orchestrating thrombotic and inflammatory responses. They promote vascular inflammation, and hence the initiation and progression of atherosclerosis, 5 in addition to accumulating with remarkable alacrity upon plaque rupture or erosion to form the nidus of occlusive arterial thrombi. Platelets contain abundant quantities of lipids, which play fundamental roles in regulating platelet structure, signalling, and, ultimately, function, including platelet activation. Chatterjee et al. 4 establish platelets as a separate compartment of lipid metabolism, including oxidation/peroxidation that can accrue specific lipid species ( Figure 1A) . Notably, platelets provide a specific, potentially shielded environment, less accessible to enzymes such as the phopholipases that can metabolize oxidized phospholipids in plasma. This is emphasized by the finding that increased oxidized LDL (oxLDL) in platelets was found to be associated with stable coronary artery disease and ST-segment elevation myocardial infarction (STEMI), 4 which stands in contrast to data demonstrating a lack of correlation between plasma oxLDL levels and cardiovascular risk. 6 Platelets may provide a unique window to view intracellular lipid metabolism, potentially reflective of the lipidome in unstable atherosclerotic plaques. This raises the intriguing prospect that the platelet lipidome may report on the atherothrombotic risk in patients. Furthermore, via platelet adhesion to atherosclerotic plaques and consequent deposition of 'pathological' lipids, the platelet lipidome indeed may not only report on, but may also directly contribute to plaque instability ( Figure 1B) . Furthermore, the platelet lipidome may also serve as a tool to monitor the efficacy of riskreducing therapeutic approaches. The continued development of liquid chromatography and mass spectrometry systems has driven the field of lipidomics over recent years. Current lipidomic strategies typically rely on either shotgunbased approaches (i.e. direct infusion into the mass spectrometer, without the use of chromatography) or chromatography-based approaches, typically using high-pressure liquid chromatography. Both these approaches have their advantages and limitations, which have been discussed in recent reviews. 7, 8 A second distinction in lipidomic strategies relates to the use of targeted or untargeted approaches. Targeted analysis relates to the foreknowledge of the lipid species to be analysed and is typically performed using liquid chromatography coupled to a triple quadrupole mass spectrometer with multiple reaction monitoring (MRM) experiments tuned to a specific set of lipid species. Untargeted analyses (as applied by Chatterjee et al.
4
) is typically performed on a high-resolution instrument, with or without chromatography, and relies on scanning experiments to capture information on all lipid species within the detection capabilities of the instrument. Subsequent statistical analyses can identify those features of interest, which can then be identified by a combination of exact mass measurement, fragmentation analysis, and database searching. While an untargeted approach provides greater potential for discovery, targeted lipidomics is more Investigating the lipidomic profile of platelets (see Figure 1 ) from patients with coronary artery disease, Chatterjee et al. 4 demonstrate that platelets from patients with acute coronary syndromes display increased loading with oxLDL. They also highlight the effect of oxLDL on the generation of reactive oxygen species and the potential for further oxidation of LDL and other lipids within the platelets themselves. Furthermore, the lipidomic profile of platelets from patients with stable coronary artery disease and STEMI is altered, displaying an increase in oxidized lipid metabolites as well as ceramides and acylcarnitines. While the study does not investigate the biological function of these lipid products, it appears that CXCL12 released from stimulated platelets acts to enhance LDL uptake into platelets via the CXCR7 receptor, to establish a feed forward mechanism where lipid uptake begets platelet activation and the further generation of oxidized lipids. Together these findings suggest that platelets are a potentially important cellular compartment that can metabolize and oxidize lipids to act as pro-thrombotic mediators and possibly promulgate vascular inflammation. These findings raise questions regarding the potential biological effects associated with the observed 'pathological' platelet lipidome. While the study demonstrates nicely the association of the aforementioned changes in patients with cardiovascular disease, we still do not know the biological effects of many of the lipid species, such as the ceramides and acylcarnitines, in the context of atherothrombosis. As such, it remains uncertain as to whether these differentially expressed lipid products are active players in disease pathogenesis or merely markers of cardiovascular disease. For example, the increased uptake of LDL particles into platelets probably leads to increased free fatty acids as a result of intracellular lipolysis. These can then feed into ceramide production as well as mitochondrial fatty acid oxidation, as indicated by the elevated ceramides and acylcarnitines, respectively. The heightened mitochondrial activity may also explain the increase in the generation of reactive oxygen species. Further investigation in this area will be important to understand fully the consequences of platelet-derived lipid products and the potential utility of therapeutic intervention aimed at these pathways. Intriguingly, one of the most strongly up-regulated lipids observed in the platelets of STEMI patients was lysophosphatidylcholine (LPC). LPC has recently been demonstrated to be enriched in microparticles released from activated platelets in patients with myocardial infarction, facilitating dissociation of pentameric C-reactive protein into its pro-inflammatory and pro-thrombotic monomeric isoform. 9 Taken together, these findings identify a novel lipid-driven, platelet-mediated inflammatory pathway. Aside from basic mechanistic questions, the application of lipidomics has potentially important clinical implications. The role of dyslipidaemia as an important risk factor for cardiovascular disease has long been recognized and has led to statins being almost universally prescribed in patients with increased cardiovascular risk given their demonstrable efficacy in both the primary and secondary prevention of coronary artery disease. 10 Recently, the novel anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, evolocumab, has demonstrated efficacy in reducing LDL-cholesterol and, most importantly, cardiovascular events. 11 Despite this, there remains some The platelet lipidome as a reflection of plaque lipid metabolism and possible player in plaque destabilisation. The platelet lipidome is altered in cardiovascular disease, displaying elevated levels of oxidized lipids, ceramides, diacylglycerol, and spingomyelin. In parallel, many of these lipid species are up-regulated in atherosclerotic plaques; thus platelets may provide a unique window into the lipid metabolism and profile associated with cardiovascular risk. Further, platelets activated by oxidized lipids may contribute to plaque instability by way of their increased propensity to adhere and aggregate, and the release of pro-inflammatory mediators, which include components of the pathological platelet lipidome. Identifying the patient with high levels of certain lipid species such as ceramides and therefore with a higher cardiovascular risk might help to identify those who will benefit from a more thorough clinical diagnostic approach and a more aggressive medical therapy including the more expensive PCSK9 inhibitors. In summary, the manuscript from Chatterjee and colleagues 4 highlights the role of platelets in the generation of lipid products, their accumulation, and potential deposition at atherosclerotic plaques. Moreover, it adds to the growing body of literature showing that oxidized lipids affect the activation state of platelets. Recent technical advances in analytical capabilities allow reliable, high-throughput lipidomic profiling of plasma and now, potentially, blood cellular compartments. Platelets are a cellular compartment of particular relevance to atherothrombosis, and therefore their specific 'pathological' lipidome is of interest as a biomarker of cardiovascular risk and as a monitoring tool of therapeutic efficacy. Ultimately, platelet lipidomic profiling has the potential to advance substantially our understanding and assessment of atherothrombotic risk.
